{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreih66hupahodvg72nefikxwiwxbrnqb3qp3c6ergrleegaxgdllykq",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mfpulxnqra62"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreigfo7isgicdznsxm57nsc46jcd72ay2tl526fom3l7g7xqpaiasde"
    },
    "mimeType": "image/jpeg",
    "size": 80327
  },
  "path": "/2026/02/25/novo-nordisk-vivtex-langer-obesity-diabetes/?utm_campaign=rss",
  "publishedAt": "2026-02-25T13:35:02.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Pharma",
    "biotechnology",
    "drug development",
    "Eli Lilly",
    "Novo Nordisk",
    "Pharmaceuticals",
    "STAT+"
  ],
  "textContent": "Novo Nordisk announced it had signed a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral obesity and diabetes drugs.",
  "title": "STAT+: Novo Nordisk strikes deal with U.S. startup to develop oral obesity, diabetes drugs",
  "updatedAt": "2026-02-25T13:35:05.000Z"
}